ES2593038T3 - Nuevo tratamiento para la amiloidosis asociada a transtirretina - Google Patents
Nuevo tratamiento para la amiloidosis asociada a transtirretina Download PDFInfo
- Publication number
- ES2593038T3 ES2593038T3 ES12778323.1T ES12778323T ES2593038T3 ES 2593038 T3 ES2593038 T3 ES 2593038T3 ES 12778323 T ES12778323 T ES 12778323T ES 2593038 T3 ES2593038 T3 ES 2593038T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- comt
- formula
- ttr
- amyloidosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| EP11382326 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2593038T3 true ES2593038T3 (es) | 2016-12-05 |
Family
ID=47076222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12778323.1T Active ES2593038T3 (es) | 2011-10-24 | 2012-10-23 | Nuevo tratamiento para la amiloidosis asociada a transtirretina |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (OSRAM) |
| EP (1) | EP2770988B1 (OSRAM) |
| JP (1) | JP6068484B2 (OSRAM) |
| KR (1) | KR102017354B1 (OSRAM) |
| CN (1) | CN103889407B (OSRAM) |
| AU (2) | AU2012327275B2 (OSRAM) |
| BR (1) | BR112014009322B1 (OSRAM) |
| CA (1) | CA2852808C (OSRAM) |
| CL (1) | CL2014000893A1 (OSRAM) |
| CY (1) | CY1118151T1 (OSRAM) |
| ES (1) | ES2593038T3 (OSRAM) |
| IL (1) | IL231907B (OSRAM) |
| MX (2) | MX385516B (OSRAM) |
| PL (1) | PL2770988T3 (OSRAM) |
| PT (1) | PT2770988T (OSRAM) |
| RU (2) | RU2747536C2 (OSRAM) |
| SG (2) | SG11201401215VA (OSRAM) |
| WO (1) | WO2013060668A1 (OSRAM) |
| ZA (1) | ZA201402546B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401215VA (en) * | 2011-10-24 | 2014-08-28 | Som Innovation Biotech S L | New therapy for transthyretin-associated amyloidosis |
| CN107106874B (zh) * | 2014-08-29 | 2021-08-31 | 阿尔尼拉姆医药品有限公司 | 治疗甲状腺素运载蛋白(ttr)介导的淀粉样变性的方法 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| BR112020018715A2 (pt) * | 2018-03-12 | 2021-01-05 | Corino Therapeutics, Inc. | Terapia de combinação para amiloidose associada a ttr |
| JP2022534420A (ja) * | 2019-05-31 | 2022-07-29 | プレックス ファーマスーティカルズ，インク | 眼のタンパク質凝集疾患を治療するための薬剤 |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| JP2025536853A (ja) * | 2022-10-10 | 2025-11-07 | コリノ セラピューティクス，インク． | 放出調節トルカポン処方剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| ATE555807T1 (de) | 2001-03-15 | 2012-05-15 | Proteotech Inc | Catechine zur behandlung der fibrillogenese bei alzheimer-krankheit, parkinson-krankheit, systemischer aa-amyloidosis und anderer amyloid- störungen |
| CN1688299A (zh) | 2002-01-29 | 2005-10-26 | 普罗特米克斯公司 | 抑制细胞毒性蛋白构象异构体 |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| AU2005215136A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | DPP-IV inhibitors for treating neurodegeneration and cognitive disorders |
| US20050261365A1 (en) | 2004-05-20 | 2005-11-24 | The Scripps Research Institute | Transthyretin stabilization |
| BRPI0514725A (pt) | 2004-08-30 | 2008-06-24 | Seo Hong Yoo | efeito neuroprotetor de udca solubilizado no modelo isquêmico focal |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| SG11201401215VA (en) * | 2011-10-24 | 2014-08-28 | Som Innovation Biotech S L | New therapy for transthyretin-associated amyloidosis |
-
2012
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2593038T3 (es) | Nuevo tratamiento para la amiloidosis asociada a transtirretina | |
| ES2749096T3 (es) | Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados | |
| JP2019142964A (ja) | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 | |
| ES2426501T3 (es) | Procedimientos de mejora de la función cognitiva utilizando compuestos no peptídicos | |
| AU2023201091B2 (en) | Cyclodextrin-Panobinostat Adduct | |
| JP7311267B2 (ja) | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 | |
| ES2358931T3 (es) | Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos. | |
| JP2022533697A (ja) | Ｇａｐｄｈを阻害する方法及び組成物 | |
| NZ623267B2 (en) | New therapy for transthyretin-associated amyloidosis | |
| HK1198432B (en) | Therapy for transthyretin-associated amyloidosis | |
| US20210069139A1 (en) | Stabilization of transthyretin tetramers in biological fluids | |
| WO2023144742A1 (en) | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases | |
| BR112018069901B1 (pt) | Aduto de ciclodextrina-panobinostat |